Overnight the company, which supplies one of Australia’s three coronavirus vaccines, applied to the US Food and Drug Administration requesting it allow the use of its product in children aged between 5 and 11.
Pfizer submitted data to the US regulator from a study of 2268 participants aged between 5 and 11 that showed the vaccine was safe for children and “and elicited robust neutralising antibody responses” in the younger participants.
